Influence of CYP2D6*5 and *10 polymorphism on the pharmacokinetics of nebivolol in healthy Chinese subjects.
Lifang GuoShumin WangZirui WanSiyang NiBenshan XuXiuli ZhaoLihong LiuPublished in: Journal of clinical pharmacy and therapeutics (2020)
Both CYP2D6*5 and *10 polymorphism altered the pharmacokinetics of nebivolol in healthy Chinese volunteers. Further studies are required to investigate the effects of these single-nucleotide polymorphisms on the pharmacokinetics, pharmacodynamics and toxicity of nebivolol.
Keyphrases